SG Americas Securities LLC cut its stake in Sanofi (NASDAQ:SNY – Get Rating) by 96.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,358 shares of the company’s stock after selling 432,605 shares during the period. SG Americas Securities LLC’s holdings in Sanofi were worth $788,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNY. Latitude Advisors LLC raised its holdings in shares of Sanofi by 33.3% during the 1st quarter. Latitude Advisors LLC now owns 10,613 shares of the company’s stock worth $545,000 after buying an additional 2,651 shares in the last quarter. Park Avenue Securities LLC raised its holdings in shares of Sanofi by 40.4% during the 1st quarter. Park Avenue Securities LLC now owns 41,226 shares of the company’s stock worth $2,117,000 after buying an additional 11,872 shares in the last quarter. FourThought Financial LLC raised its holdings in shares of Sanofi by 4.4% during the 1st quarter. FourThought Financial LLC now owns 8,972 shares of the company’s stock worth $458,000 after buying an additional 377 shares in the last quarter. Addison Advisors LLC raised its holdings in shares of Sanofi by 93.5% during the 1st quarter. Addison Advisors LLC now owns 1,873 shares of the company’s stock worth $96,000 after buying an additional 905 shares in the last quarter. Finally, Summit Global Investments raised its holdings in shares of Sanofi by 2.5% during the 1st quarter. Summit Global Investments now owns 39,522 shares of the company’s stock worth $2,029,000 after buying an additional 968 shares in the last quarter. 12.82% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on SNY shares. Guggenheim boosted their price target on Sanofi from €121.00 ($124.74) to €127.00 ($130.93) in a report on Monday, May 2nd. Credit Suisse Group boosted their price objective on Sanofi from €105.00 ($108.25) to €110.00 ($113.40) and gave the stock an “outperform” rating in a research report on Friday, July 22nd. Barclays boosted their price objective on Sanofi from €90.00 ($92.78) to €105.00 ($108.25) in a research report on Thursday, April 14th. JPMorgan Chase & Co. boosted their price objective on Sanofi from €105.00 ($108.25) to €115.00 ($118.56) in a research report on Monday. Finally, SVB Leerink began coverage on Sanofi in a research report on Monday, May 23rd. They set an “outperform” rating on the stock. One analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Sanofi has an average rating of “Moderate Buy” and a consensus target price of $111.14.
Sanofi Trading Down 1.6 %
Sanofi Company Profile
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
- Get a free copy of the StockNews.com research report on Sanofi (SNY)
- MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
- The Colgate-Palmolive Growth Outlook Brightens
- Deep Value High Yield Newell Brands Is Ready To Bottom
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian’s Stock Still Have A Future?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.